Tsuruta Yusuke, Nakamura Mitsuhiro, Miyabe Yuki, Nakata Manabu, Ishihara Yoshitomo, Mukumoto Nobutaka, Akimoto Mami, Ono Tomohiro, Yano Shinsuke, Higashimura Kyoji, Matsuo Yukinori, Mizowaki Takashi, Hiraoka Masahiro
Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto 606-8507, Japan.
Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Phys Med. 2017 Dec;44:86-95. doi: 10.1016/j.ejmp.2017.07.020. Epub 2017 Jul 29.
To verify lung stereotactic body radiotherapy (SBRT) plans using a secondary treatment planning system (TPS) as an independent method of verification and to define tolerance levels (TLs) in lung SBRT between the primary and secondary TPSs.
A total of 147 lung SBRT plans calculated using X-ray voxel Monte Carlo (XVMC) were exported from iPlan to Eclipse in DICOM format. Dose distributions were recalculated using the Acuros XB (AXB) and the anisotropic analytical algorithm (AAA), while maintaining monitor units (MUs) and the beam arrangement. Dose to isocenter and dose-volumetric parameters, such as D, D, D and D, were evaluated for each patient. The TLs of all parameters between XVMC and AXB (TL) and between XVMC and AAA (TL) were calculated as the mean±1.96 standard deviations.
AXB values agreed with XVMC values within 3.5% for all dosimetric parameters in all patients. By contrast, AAA sometimes calculated a 10% higher dose in PTV D and D than XVMC. The TL and TL of the dose to isocenter were -0.3±1.4% and 0.6±2.9%, respectively. Those of D were 1.3±1.8% and 1.7±3.6%, respectively.
This study quantitatively demonstrated that the dosimetric performance of AXB is almost equal to that of XVMC, compared with that of AAA. Therefore, AXB is a more appropriate algorithm for an independent verification method for XVMC.
使用二级治疗计划系统(TPS)作为一种独立的验证方法来验证肺部立体定向体部放射治疗(SBRT)计划,并确定肺部SBRT中一级和二级TPS之间的耐受水平(TLs)。
总共147个使用X射线体素蒙特卡罗(XVMC)计算的肺部SBRT计划以DICOM格式从iPlan导出到Eclipse。使用Acuros XB(AXB)和各向异性分析算法(AAA)重新计算剂量分布,同时保持监测单位(MUs)和射束排列。对每位患者评估等中心剂量和剂量体积参数,如D、D、D和D。计算XVMC与AXB之间(TL)以及XVMC与AAA之间(TL)所有参数的TLs,计算方法为均值±1.96标准差。
对于所有患者的所有剂量学参数,AXB值与XVMC值在3.5%以内相符。相比之下,AAA有时在PTV D和D中计算出的剂量比XVMC高10%。等中心剂量的TL和TL分别为-0.3±1.4%和0.6±2.9%。D的TL分别为1.3±1.8%和1.7±3.6%。
本研究定量证明,与AAA相比,AXB在剂量学性能上几乎与XVMC相当。因此,AXB是用于XVMC独立验证方法的更合适算法。